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Nursing	Implications
Pathophysiology	of	Heart	Failure
Tori	Morrow	RN,	BSN
Introduction
• According	 to	 Nicholson	(2014),	 s igns 	of	heart	 failure	
include	 tachypnea,	 tachycardia,	 abnormal	 pulse,	
displaced	 apex	beat,	 extra	 heart	 sound,	 raised	
jugular	 venous 	 pressure,	 heart	 murmurs ,	 wheez ing,	
lung	 crepitus ,	 weight	 gain	and	 edema,	 pleural	
effus ions ,	 hepatomegaly,	 and	tissue	 wasting.	Many	
of	 these	s igns 	are	 caused	by	abnormalities 	 of	 the	
myocardial	 tis sue	as 	a	result	 of	 the	 compensatory	
mechanisms 	 that	 produce	 fluid	retention	 and	
vasoconstriction	 in	order	 to	improve	 cardiac	output	
and	 perfus ion.
• According	 to	 Nicholson	(2014),	 symptoms	 of	 heart	
failure	 include	 breathlessness ,	 orthopnea,	
paroxysmal	 nocturnal	 dyspnea,	 nocturnal	 cough,	
s leep	disorders ,	 fatigue,	 reduced	 exercise	tolerance,	
peripheral	 edema,	 loss 	of	 appetite,	 bloated	 feeling,	
confus ion,	 palpitations ,	 angina,	 syncope,	
depress ion	 and	 anxiety.	
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As 	s tated	 previous ly,	 the	 disease	process 	of	 heart	 failure	 can	
be	caused	 by	multiple	 factors .	 There	 are	three	 contributors 	 to	
heart	 contractibility,	 these	 include	 preload,	 contractility,	 and	
afterload,	 which	 all	impact	 s troke	volume	 (Lekavich et	al.,	2015).	
Preload	 is 	the	 volume	 of	 blood	 filling	the	 ventricle	 before	 it	
contracts ,	 where	 afterload	 is 	referred	 to	 as 	the	 pressure	 the	
ventricle	 has 	to	 work	 against	when	 ejecting	 blood	 out	 of	the	
ventricles 	 generated	 by	the	 pulmonary	 and	 systemic	circulatory	
systems	(Casey,	2013,	 p.	22).	 Preload	 is 	reflected	 by	blood	
volume,	 therefore	 a	change	in	 levels 	alters 	preload	 and	s troke	
volumes .	 Afterload	 increases 	 with	a	rise	 in	peripheral	 vascular	
res is tance,	 caus ing	the	 ventricles 	 to	work	 harder	 than	 normal.	
Contractility	 is 	referred	 to	 as 	the	 heart	 muscle’s 	ability	 to	eject	
the	 blood	 out	 of	the	 ventricles 	 (Casey,	 2013,	p.	 22).	Contractility	
is 	most	often	 altered	 as 	a	result	 of	 damage	 after	 a	heart	 attack.	
Contractility	 can	 also	be	altered	 by	 changes 	in	blood	 calcium	
level,	a	process 	 that	 occurs 	with	 myocardial	 cell	injury,	 which	
reduces 	 cardiac	output	 (Marín-García,	 2016).	
• For	nurses 	taking	 care	of	patients 	 with	heart	
failure,	 it	is 	important	 to	 cons ider	all	factors 	
when	address ing	 their	 care.	The	patient	 and	
family	should	most	 importantly	 be	educated	
on	the	 disease	itself	in	order	 to	improve	 self-
management.	 Lifestyle	changes 	commonly	
recommended	 include	smoking	cessation,	
decreased	alcohol	consumption,	 and	increase	
in	exercise	(Nicholson,	2014).	As 	noted	 by	
Casey	(2013),	 emphas is 	was 	placed	on	the	
importance	 of	 diet	modification	 including	low	
sodium	and	 fluid	intake,	in	 addition	 to	close	
monitoring	 of	daily	weights 	(p.	23).	 A	note	
should	be	given	to	 care	providers 	 to	address 	
the	 topic	of	depress ion	 s ince	the	prevalence	
among	 those	diagnosed	with	 heart	 failure	is 	
high.	
• Appropriate	 control	 of	 comorbidities 	 such	as 	
diabetes ,	hypercholesterolemia	 and	kidney	
disease	improves 	cardiac	outcomes 	 (Nicholson,	
2014).	 Proper	 interventions 	 should	 be	
adminis tered	 based	off	 of	the	 patient’s 	
presenting	 s igns 	and	symptoms.	
• The	goal	of	 treatment	 is 	to	improve	 life	
expectancy	and	quality	 of	life.	Common	
pharmacological	 s trategies 	include	the	 use	of	
angiotens in-converting	 enzyme	(ACE)	
inhibitors ,	 diuretics ,	and	 beta-adrenoceptor	
blockers 	(beta	 blockers ).
• ACE	 inhibitors are	prescribed	 to	 patients 	firs t	
in	HFrEF due	to	 their	 ability	to	 hinder	 the	
productions 	 of	 angiotens in	II	caus ing	arteriole	
vasodilation	(Lekavich et	al.,	2015).	 Therefore,	
they	reduce	 preload	 and	afterload.	
• Diuretics 	are	 recommended	 for	 all	types 	of	
heart	 failure	 for	their	 capability	 of	reducing	
fluid	retention	 and	 overload,	therefore	
relieving	the	 patient’s 	 symptoms	of	heart	
failure	 (Reddy	&	Borlaug,	 2016).	 As 	a	result	of	
excess 	fluid	being	excreted,	preload	 is 	reduced.
• Beta	 blockers 	are	typically	given	in	addition	 to	
ACE	 inhibitors 	due	 to	their	 ability	 to	decrease	
the	 heart	 rate	and	 therefore	 prolong	 diastole	
and	improve	 ventricular	 filling	(Reddy	 &	
Borlaug,	 2016).	
•As 	a	nurse	 in	the	 Emergency	 Department	 at	Mount	
Carmel	 West,	many	 patients 	 come	 in	exhibiting	 s igns 	
and	 symptoms	 of	heart	 failure.	 Not	every	 patient	
displays 	the	 same	symptoms	 and	 not	 all	patients 	 are	
on	 the	same	 treatment	 regimen.	 It	 is 	beneficial	for	
nurses 	 taking	care	 of	these	 patients 	 to	 be	
knowledgeable	 on	the	 disease	process 	and	 what	
symptoms	 patients 	 can	experience.	
•Heart	 failure	 can	be	 defined	 as 	the	 inability	 of	the	
heart	 to	 pump	 effectively	 enough	 to	meet	 metabolic	
demands 	 of	 the	 body’s 	tis sues 	(Lodge	 &	Yousef,	2016,	
p.	S12).	 This 	could	 be	caused	by	 damage	 to	cardiac	
tis sue	or	 as 	a	result	 of	disease	process 	 (Casey,	2013,	 p.	
20).	 Many	 patients 	 have	multiple	 medical	 conditions 	
that	 can	contribute	 to	heart	 failure.	 As 	a	result,	
compensatory	 mechanisms 	 may	be	 initiated	 to	
counteract	 the	 s ide	effects 	 of	the	 disease	caus ing	
systemic	changes .	
• The	 prevalence	 of	this 	 disease	is 	very	high	 in	the	
United	 States ,	 and	it	 is 	going	to	continue	 to	 rise.	
According	 to	 Reddy	 &	Borlaug	 (2016),	 it	is 	expected	
that	 approximately	 8	million	 adults 	 in	the	 United	
States 	 will	have	heart	 failure	 in	2030.	 Prognos is 	 is 	
often	 poor	 and	quality	 of	 life	for	 patients 	 is 	
diminished,	 caus ing	 s tress 	and	hardship	 for	 patients 	
and	 their	 family	 members .	 Roughly	 half	 of	 the	 people	
who	 develop	 heart	 failure	 die	 within	 five	years 	of	
diagnos is 	(Briasoulis ,	 Androulakis ,	 Chris tophides ,	 &	
Tousoulis ,	2016).
•With	 such	a	widespread	 disease,	it	 is 	vital	that	
healthcare	 providers 	 become	 familiar	 with	disease	
presentation,	 contributing	 factors ,	 and	 treatment	
options .	 According	 to	Reddy	 &	Borlaug	 (2016),	 the	
cost	of	 healthcare	 for	 heart	 failure	 was 	estimated	 to	
be	$21	 billion	 in	2012.	 Consequently,	 it	is 	important	
for	 an	advanced	 practice	 nurse	 frequently	
encountering	 these	 patients 	 to	 understand	 the	
pathophys iology	 behind	 the	 disease	process 	to	
determine	 the	 proper	 choice	of	 treatment	 to	 help	
further	 reduce	 cost.
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Heart	 failure	 is 	a	common	disease	that	 exis ts 	
always 	in	the	presence	of	 other	 ailments .	The	
detriment	 of	the	 illness 	can	be	monumental	 for	
patients 	 and	families .	With	the	 improvement	 of	
health	 care	quality,	the	 occurrence	is 	expected	to	
increase.	Knowing	 the	pathophys iology	 allows 	
the	 caregiver	to	 appropriately	 determine	 what	
treatment	 is 	the	best	choice	for	 that	 patient.	 The	
choice	of	treatment	 should	 always 	be	specific	to	
the	 patient	 based	off	of	 their	 current	 disease	
process 	and	include	the	 patient’s 	 wishes .	
Success ful	management	 can	result	in	decrease	
hospital	admiss ions 	and	improved	 quality	 of	life.
Conclusion
Risk	Factors
• Common	 causes 	of	heart	 failure	 are	 ischemic	heart	 disease,	myocardial	 infarction,	 hypertens ion,	 and	
arrhythmias 	 (Nicholson,	 2014).	 Other	 causes 	include	 cardiomyopathies ,	 myocarditis ,	 valve	disorders ,	
amyloidos is ,	 sarcoidos is ,	and	 excess ive	alcohol	use	(Nicholson,	2014).
• Risk	factors 	 for	 diastolic	heart	 failure	 are	 well	es tablished	 and	include	 hypertens ion,	 older	 age	
(especially	in	 women),	 kidney	 disease,	anemia,	 diabetes ,	 coronary	 artery	 disease,	 sedentary	 lifes tyle,	
and	 obes ity	(Reddy	 &	Borlaug,	 2016).	 Komomura (2013)	 points 	 out	 the	 s ignificant	 finding	 of	a	high	
comorbidity	 rate	 of	 obes ity,	diabetes ,	 and	 chronic	 kidney	 disease	with	diastolic	 heart	 failure,	 therefore	
emphas iz ing	 the	 importance	 of	 patient	 education	 and	lifes tyle	 modification.	
• The	 greatest	 risk	factors 	 for	 systolic	heart	 failure	 are	 myocardial	 infarction	 and	 hypertens ion	 (Reddy	 &	
Borlaug,	 2016).	 Hypertens ion	 increases 	 peripheral	 vascular	res is tance,	 therefore	 caus ing	the	 left	
ventricle	 to	 work	 harder,	 dilate,	 and	 have	decreased	 contractility.	
• Right	 s ided	heart	 failure	 is 	commonly	 associated	 with	pulmonary	 disease	when	 not	 related	 to	left	
ventricular	 dys function.	 Chronic	 obstructive	 pulmonary	 disease	(COPD)	 causes 	res is tance	 against	the	
right	 ventricle	 when	 pumping	 blood	 into	 the	 pulmonary	 circulation,	 bringing	 about	 damage.
Significance	of	Pathophysiology
Understanding	 the	 pathophys iology	 allows 	caregivers 	to	 determine	 what	 type	 of	 heart	 failure	 the	
patient	 has 	and	what	 s igns 	and	symptoms	 to	 expect.	 This 	information	 also	provides 	 the	caregiver	 with	
knowledge	 of	 other	 diseases 	the	 patient	 is 	at	risk	for	 and	what	 illnesses 	may	have	 contributed	 to	 the	
patient’s 	 heart	 failure.	 It	is 	vital	for	 the	 provider	 to	 understand	 all	factors 	 and	 manifestations 	 the	 patient	
has 	in	order	 to	 properly	 identify	 the	 patient’s 	 ability	 for	 treatment	 and	 recovery.	 There	 are	 several	
different	 types 	 of	heart	 failure.	 These	include	 left	 ventricular	 failure	 (systolic	and	 diastolic	heart	 failure)	
and	 right	 ventricular	 failure.
Systolic	Heart	Failure
Systolic	heart	 failure	 is 	the	inability	 of	 the	 left	
ventricle	 to	 contract	 effectively	 caus ing	 reduced	
blood	 circulation	 to	 the	 body	 (Casey,	2013,	 p.	21).	
Often,	 it	 is 	referred	 to	as 	heart	 failure	 with	
reduced	 ejection	 fraction	 (HFrEF).	 Ejection	
fraction	 is 	s imply	the	percentage	 of	 blood	 coming	
out	 of	 the	left	 ventricle	 with	each	 contraction.	
Diagnos is 	 of	HFrEF is 	an	ejection	 fraction	 <40%	
with	 a	normal	 being	 >50%	 (Reddy	 &	Borlaug,	
2016).	 The	 dis tinguishing	 factors 	 in	systolic	heart	
failure	 is 	ventricular	 dilatation	 and	 markedly	
depressed	 contractility	 (Reddy	 &	Borlaug,	 2016).	
The	 chief	outcomes 	 of	 HFrEF are	 pulmonary	
congestion	 due	 to	increase	 in	atrial	 pressure	 and	
poor	 circulation	 due	to	 decreased	 cardiac	 output.
RAAS
When	 the	heart	 is 	unable	 to	effectively	 function	 as 	a	pump	 the	
renin-angiotens in-aldosterone	 system	(RAAS)	 is 	activated.	
Decreased	 blood	 flow	due	 to	 poor	 cardiac	output	 s timulates 	 the	
kidneys 	to	 release	 renin,	 which	turns 	 angiotens inogen	 into	
angiotens in	 II	 (Lodge	&	Yousef,	 2016,	p.	 S13).	 Angiotens in	 II	 has 	
detrimental	 effects 	to	 cardiac	 tis sue.	When	there	 are	 cons is tent	
elevated	 levels 	of	 Aldosterone	 II,	vasoconstriction	 occurs 	
caus ing	an	increase	 in	blood	 pressure	 and	myocyte	 hypertrophy	
(Lodge	 &	Yousef,	2016,	 p.	S14).	 The	synthes is 	 of	aldosterone	 is 	
s timulated	 by	angiotens in	 II	(Sousa-Pinto,	 Ferreira-Pinto,	 Santos ,	
&	Leite-Moreira,	 2014).	 Aldosterone	 is 	a	hormone	 that	 causes 	
sodium	 and	 water	 retention,	 which	 increases 	blood	 volume,	 and	
cardiac	output	 (Lodge	 &	Yousef,	 2016,	p.	 S14).	Increased	 blood	
volume	 due	 to	aldosterone	 and	 vasoconstriction	 from	
angiotens in	 II,	 causes 	further	 myocyte	 damage	 and	fibros is 	
occurs .	Another	 hormone	 that	 retains 	 water	 and	 causes 	
vasoconstriction	 is 	arginine	 vasopress in	(antidiuretic	 hormone	
[ADH]).	 ADH	 is 	released	as 	a	result	 of	 atrial	 s tretching	 and	 a	
decrease	 in	cardiac	 output	 (Lodge	 &	Yousef,	 2016,	p.	 S14).	
Overstretching	 as 	a	result	 of	increased	 volume,	 therefore	
increased	 preload,	 decreases 	 cardiac	output.	 Afterload	 is 	
increased	 due	 to	vasoconstriction	 and	 water	 retention,	 caus ing	
the	 heart	 to	 increase	 workload	 resulting	 in	 an	increase	in	
metabolic	 demands .	 When	the	 myocytes 	 are	unable	 to	 keep	up	
with	 demands ,	 hypertrophy	 and	remodeling	 occurs .	 This 	
perpetuates 	 the	 cycle	of	 heart	 failure.
SNS
When	 there	 is 	a	decrease	 in	blood	 pressure	 and	 cardiac	output,	
the	 sympathetic	 nervous 	 system	 (SNS)	is 	activated.	 Stimulation	
of	 the	sympathetic	 nervous 	 system	generates 	 the	release	 of	
noradrenaline	 (norepinephrine),	 which	triggers 	 beta-receptors 	
to	 increase	heart	 rate,	 s trength	 and	 speed	 of	contractions 	
(Casey,	2013,	 p.	22).	 As 	a	result	 of	 increased	 heart	 rate,	 the	
ventricles 	 begin	 to	thicken	 (hypertrophy)	 and	 collagen	
depos ition	 occurs ,	caus ing	dys function,	 this 	is 	called	
remodeling	 (Andersen,	 Andersen,	 de	 Man,	 &	Nielsen-Kudsk,	
2015).	 Ventricular	 hypertrophy	 has 	a	s ignificantly	 negative	
effect	 on	 the	heart’s 	 contractility.	 Mechanical	 s timulation	 to	 the	
myocardium	 is 	the	main	 factor	 of	 myocardial	 hypertrophy,	
whereas 	 myocardial	 fibros is 	 may	be	 caused	by	neurohumoral
compensatory	 mechanisms 	 such	as 	cytokines 	and	 hormones 	
(Komamura,	 2013).	 Overtime,	 this 	 compensatory	 mechanism	
can	become	 toxic	to	 the	 heart	 cells ,	therefore	 rendering	 the	
cells 	unable	 to	respond	 to	the	 body’s 	 attempts 	 to	 compensate.	
Signs	and	Symptoms
Left	Heart	Failure	versus	Right	Heart	Failure
Left	 heart	 failure	 is 	commonly	 called	 congestive	heart	 failure	 (CHF).	 It	can	be	 further	 categorized	 by	
systolic	heart	 failure	 or	 diastolic	 heart	 failure	 based	 off	of	 ejection	 fraction.	 Left	 heart	 failure	 is 	essentially	
the	 incapability	 of	 the	heart	 to	 perfuse	 the	 body’s 	vital	 organs .	Right	 heart	 failure	 is 	the	 inability	 of	the	
heart	 to	 adequately	 perfuse	 the	 pulmonary	 circulation.	 Right	 heart	 failure	 is 	caused	by	increased	
res is tance	 of	the	 pulmonary	 circulation,	 caus ing	the	 right	 ventricle	 to	 fail.	Left	 heart	 failure	 is 	correlated	
with	 pulmonary	 edema	 whereas 	 right	 heart	 failure	 is 	connected	 to	peripheral	 and	visceral	edema	 (Casey,	
2013,	 p.	21).	 	Most	 often,	 right	 heart	 failure	 occurs 	 as 	a	result	of	 left	 s ided	heart	 failure.	
Diastolic	Heart	Failure
Diastolic	 heart	 failure	 is 	referred	 to	 as 	heart	 failure	
with	 preserved	 ejection	 fraction	 (HFpEF).	 Diastolic	
heart	 failure	 is 	when	a	normal	 ejection	 fraction	
occurs 	with	 impaired	 left	 ventricular	 relaxation.	
Typically,	diagnos is 	of	 HFpEF is 	an	ejection	 fraction	
of	 >50%,	which	 is 	normal	 (Lekavich et	 al.,	2015).	
Myocardial	 fibros is 	or	 hypertrophy	 occur	often	 as 	a	
result	 of	 hypertens ion,	 ending	 in	increased	 left	
ventricular	 s tiffness 	with	 decreased	 filling	 ability	
(Komamura,	 2013).	 The	left	 ventricle	 is 	not	 filling	
enough	 in	 diastole,	so	to	 compensate,	 preload	 is 	
increased,	 which	in	 turn	 increases 	left	 atrial	
pressure	 and	 as 	a	result,	 directly	 causes 	pulmonary	
congestion	 (Komamura,	 2013).	
Remodeling
According	 to	 Marín-García (2016),	 “three	 major	 cell	death	
modalities ,	 apoptos is ,	 necros is 	 and	autophagy,	 occur	in	
cardiomyocytes ,	 and	both	 gradual	 and	acute	 cell	death	 are	
features 	 of	 the	 cardiac	pathophys iology,	 including	 ischemia,	
myocardial	 infarction,	 and	 progress ive	 heart	 failure”	 (p.	 1).	
Inflammation	 is 	important	 to	 repair	 damaged	 tissue,	 but	 over	
activation	 can	cause	extens ive	 destruction.	 As 	a	result	 of	
prolonged	 inflammation,	 especially	in	later	 s tages 	of	 heart	
failure,	 hypertrophy,	 fibros is ,	 and	cell	death	 occur	 in	cardiac	
tis sue,	which	 is 	known	as 	remodeling	 (Briasoulis ,	 Androulakis ,	
Chris tophides ,	 &	Tousoulis ,	2016).	 Damaged	 myocardium	
produces 	 reactive	 oxygen	 species 	(ROS)	which	 causes 	s tress ,	
inflammation,	 and	cell	death,	 resulting	 in	the	 release	 of	pro-
inflammatory	 cytokines 	interleukin	 -1	 (IL-1)	 and	TNF-α (Sousa-
Pinto,	 Ferreira-Pinto,	 Santos ,	 &	Leite-Moreira,	 2014).	 These	
molecules 	 exacerbate	 heart	 failure	 by	increas ing	 leukocyte	
attraction,	 proliferating	 the	 inflammatory	 response,	 and	
increas ing	 endothelial	 destruction.	 Endothelial	 destruction	
causes 	a	reduced	 production	 of	 nitric	 oxide	 (a	known	
vasodilator)	 therefore	 resulting	 in	vasoconstriction	 (Briasoulis ,	
Androulakis ,	 Chris tophides ,	 &	Tousoulis ,	2016).	
Vasoconstriction	 continues 	 to	 s timulate	 the	 neurohumoral and	
inflammatory	 response,	 therefore	 proliferating	 the	 cycle	of	
damage.	
